A Turning Point in Treatment Paradigms Targeting the Root Cause

Existing treatments for Non-Cystic Fibrosis Bronchiectasis (NCFBE) have primarily focused on managing symptoms, such as mucus clearance or antibiotic administration. However, with the approval of Brensocatib (Brinsupri) from Insmed (INSM) as the first targeted therapy, disease-modifying treatment to slow disease progression is now possible. Brensocatib received FDA approval in August 2025 and EMA approval in November 2025, marking a turning point in the global NCFBE treatment market, valued at $1.45 billion. This novel drug has demonstrated commercial value by effectively inhibiting patients' recurrent pulmonary exacerbations through the regulation of the underlying neutrophilic inflammatory response.

Clinical Validation of the Dipeptidyl Peptidase 1 Inhibition Mechanism

The core mechanism of Brensocatib involves the selective inhibition of Dipeptidyl Peptidase 1 (DPP1, Cathepsin C), an enzyme in neutrophils that causes damage to airway tissue. In the Phase 3 ASPEN trial, involving over 1,700 patients, once-daily oral administration of Brensocatib significantly reduced the rate of pulmonary exacerbations compared to placebo. Notably, the FDA granted approval without holding a separate advisory committee (AdComm) meeting and approved its use in all patients aged 12 years and older, while the EMA limited its use to high-risk patients with two or more exacerbations per year, highlighting differences in market entry strategies. This success has established the commercial potential of a new target that blocks the activation of inflammatory signals within the industry.

Competition from Subsequent Pipeline Products, Including Boehringer Ingelheim

The approval of Brensocatib demonstrates the unmet needs in the market and is accelerating the development competition among multinational pharmaceutical companies. Boehringer Ingelheim has initiated the Phase 3 AIRTIVITY study with Verducatib (BI 1291583), which has the same DPP1 inhibition mechanism, to evaluate its efficacy and ability to delay lung function decline. AstraZeneca (AZN) is conducting a Phase 2b CLEAR study with Gremubamab, a bispecific antibody targeting chronic Pseudomonas aeruginosa, to inhibit biofilm formation. As the pipeline diversifies, a personalized treatment environment based on patient profiles is expected to emerge.

Addressing Unmet Medical Needs Through the Introduction of Next-Generation Treatment Technologies

Unlike the past, where simple antibiotic approaches like liposomal ciprofloxacin failed, the market now demands precise, innovative biological therapies. Armata (ARMP)'s inhaled bacteriophage AP-PA02, which has completed Phase 2 trials, has demonstrated safety and significant reduction in bacterial load in patients with chronic Pseudomonas infections, highlighting its potential as a next-generation technology. Sanofi (SNY) and Regeneron (REGN) are also conducting Phase 2 studies with Itepekimab, an anti-IL-33 monoclonal antibody, to target specific subgroups of patients. Ultimately, the NCFBE treatment market will evolve around phenotype-based personalized targeted therapies, becoming a new growth engine for multinational pharmaceutical companies.